

# **iLite<sup>®</sup> ADCC mVEGF**

## **ASSAY READY CELLS**


**iLite<sup>®</sup> ADCC anti-mVEGF Activity Assay** is designed to enable determination of the ADCC activity of existing or new anti-VEGF drug candidates. The **iLite<sup>®</sup> ADCC Assay Ready Cells** are engineered cells that enable antibody-dependent cell-mediated cytotoxicity (ADCC) to be examined through the specific expression of Firefly luciferase.

The idea of employing ADCC (antibody-dependent cell-mediated cytotoxicity) to destroy dysfunctional cells by treating patients with antibodies has existed since the discovery of the ADCC mechanism.

The **iLite ADCC anti-mVEGF Assay Ready Cells** are genetically engineered cell lines, optimized and matched to give high sensitivity and specificity in an anti-VEGF ADCC activity assay which can be run within one workday and does not require any cell culturing.

**iLite ADCC Effector (V) Assay Ready Cells** are human cells which express high levels of FcγRIIIa (CD16) and signals to a Firefly Luciferase (FL) reporter gene. The cells are engineered to have a high tolerance for serum, and include a second reporter gene, Renilla Luciferase (RL), which allows for normalization of cell counts, serum matrix effects or lysis of the effector cells by the target cells.

The **iLite ADCC Target mVEGF (+) Assay Ready Cells** are human cells engineered to overexpress constant levels of membrane bound VEGF and optimized to give high sensitivity and specificity when used together with **iLite ADCC Effector (V) Assay Ready Cells**. Since unspecific activation of ADCC can be a confounding factor when performing ADCC assays, we have also developed **iLite ADCC Target mVEGF (-) Assay Ready Cells** which are depleted of membrane bound VEGF expression, to be used as a control.



*iLite<sup>®</sup> mVEGF Target Assay Ready Cells can be used for assessing the possibility of an anti-VEGF antibody drug inducing ADCC.*

- Unparalleled sensitivity
- Normalization readout available
- High precision, due to Assay Ready Target cells with a constant high expression of mVEGF
- Assay Ready Target negative cells for use as internal control and background adjustment

<b>iLite<sup>®</sup> ADCC mVEGF Assay Ready Cells</b>		
<b>Product code</b>	BM5001	<i>iLite<sup>®</sup></i> ADCC Effector (V) Assay Ready Cells
	BM5017	<i>iLite<sup>®</sup></i> mVEGF (+) Target Assay Ready Cells
	BM5018	<i>iLite<sup>®</sup></i> mVEGF (-) Target Assay Ready Cells
<b>Host Cell</b>	For BM5001: Human T lymphocyte cell line, Jurkat (ATCC #TIB-152) For BM5017, BM5018: Human embryonic kidney cell line, HEK293 <sup>1</sup> (ATCC# CRL-1573)	
<b>Format</b>	Assay Ready Cells	
<b>Application</b>	The <i>iLite<sup>®</sup></i> ADCC Effector (V) Assay Ready Cells can be used together with matched <i>iLite<sup>®</sup></i> ADCC Target mVEGF (+) and <i>iLite<sup>®</sup></i> ADCC Target mVEGF (-) Assay Ready Cells for the quantification ADCC activity. <ul style="list-style-type: none"> <li>• Quantification of anti-mVEGF ADCC activity (LABEL-DOC-0494)</li> </ul>	
<b>Assay time</b>	4 hours (incubation)	
<b>Detection system</b>	Luminescence	
<b>Availability</b>	Research Use Only (RUO)*	

<sup>1</sup> The HEK-293 cell line has been used under a license obtained from AdVec Inc.

\*These products are intended for professional research use only. The data and results originating from using the products, should not be used either in diagnostic procedures or in human therapeutic applications.

In accepting delivery of *iLite<sup>®</sup>* Assay Ready Cells the recipient agrees not to sub-culture these cells, attempt to sub-culture them or to give them to a third party, and recipient is only to use them directly in assays. The *iLite<sup>®</sup>* cell-based products are covered by patents which are the property of Svar Life Science AB and any attempt to reproduce the delivered *iLite<sup>®</sup>* Assay Ready Cells would constitute an infringement.

### **Svar Life Science AB**

T +46 40 53 76 00  
E info@svarlifescience.com  
W www.svarlifescience.com

